Cytochrome P-450 CYP2C19

A cytochrome P-450 enzyme subtype that oxidizes several important groups of drugs including many PROTON PUMP INHIBITORS and ANTICONVULSANTS.

Also Known As:

CYP2C19; CYPIIC19; S-Mephenytoin 4'-Hydroxylase; 4'-Hydroxylase, S-Mephenytoin; CYP2C19, Cytochrome P-450; Cytochrome P 450 CYP2C19; P-450 CYP2C19, Cytochrome; S Mephenytoin 4' Hydroxylase

Networked: 1237 relevant articles (77 outcomes, 321 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Wang, Yongjun: 18 articles (11/2022 - 07/2016)
2.	Meng, Xia: 16 articles (11/2022 - 07/2016)
3.	Furuta, Takahisa: 16 articles (04/2016 - 02/2002)
4.	Wang, Yilong: 15 articles (11/2022 - 07/2016)
5.	Nakagawa, Kazuko: 15 articles (06/2017 - 02/2007)
6.	Zhao, Xingquan: 14 articles (11/2022 - 07/2016)
7.	Liu, Liping: 13 articles (11/2022 - 07/2016)
8.	Li, Hao: 13 articles (01/2022 - 07/2016)
9.	Pan, Yuesong: 12 articles (11/2022 - 07/2016)
10.	Kaikita, Koichi: 12 articles (01/2018 - 03/2011)

Related Diseases

1.	Stroke (Strokes) 12/01/2021 - "This study investigates whether carrying CYP2C19 loss-of-function (LOF) alleles affects the risk of recurrent stroke in IS patients. " 03/01/2012 - "In our study the CYP2C19 genotype was determined in one Hungarian sample of 354 stroke patients and 221 healthy controls. " 12/01/2023 - "Inconclusive and limited results have been reported on the clinical utility of CYP2C19 genotyping in stroke/TIA patients of non-East Asian ancestries. " 09/11/2023 - "This suggests patients with CYP2C19 loss-of-function alleles represent a subpopulation that is inherently different from the general stroke population in their antiplatelet response. " 05/01/2023 - "Conclusion CYP2C19 polymorphisms may play a significant role in the pathogenesis of stroke. "
2.	Infections 01/01/2019 - "pylori infection as first line treatment irrespective of CYP2C19 and antibiotic resistance pattern. " 01/01/2015 - "This study was aimed to investigate the impact of CYP2C19 genotypic polymorphism in HCC related to chronic HBV infection in Thailand. " 12/20/2022 - "pylori ) infection status and CYP2C19 polymorphism on anaprazole. " 01/01/2021 - "pylori infection guided by determination of antibiotic resistance and CYP2C19 polymorphism using visual gene chip technology may provide high clinical effectiveness as initial H. " 01/02/2020 - "Conclusion: Eradication regimen based on bacterial susceptibility and CYP2C19 genotype should be considered in children with refractory Hp infection. "
3.	Hemorrhage 10/01/2023 - "Among CYP2C19 LOF carriers undergoing PCI, a genetic-guided strategy resulted in a statistically significant reduction in cumulative ischemic events without a significant difference in bleeding. " 12/15/2016 - "The aim of this study was to check if CYP2C19/ABCB1-genotype-guided strategy reduces the rates of cardiovascular events and bleeding. " 01/01/2016 - "Most studies indicated that low on-treatment platelet reactivity (LTPR), as measured by several platelet function tests, and the carriage of CYP2C1917 allele were independent risk factors for bleeding. " 09/01/2012 - "The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study." 01/01/2022 - "CYP2C1917 carriers were found to be associated with increased risk of bleeding (OR, 21.6; 95% CI, 4.8-96.8; P < 0.0001). "
4.	Transient Ischemic Attack 01/01/2023 - "This was a prespecified analysis of the CHANCE-2 trial, which enrolled 6412 patients with minor stroke or transient ischemic attack who carried CYP2C19 loss-of-function alleles. " 12/30/2021 - "We conducted a randomized, double-blind, placebo-controlled trial at 202 centers in China involving patients with a minor ischemic stroke or transient ischemic attack (TIA) who carried CYP2C19 loss-of-function alleles. " 03/22/2023 - "The frequency of CYP2C19 loss-of-function variants in patients with non-cardioembolic ischemic stroke or transient ischemic attack in the Dutch population." 01/01/2023 - "Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective." 11/01/2022 - "CYP2C19 loss-of-function allele carriers with minor stroke or transient ischemic attack. "
5.	Peptic Esophagitis (Reflux Esophagitis) 12/01/2014 - "This study compared the effect of two PPIs on early symptom relief in Japanese patients with reflux esophagitis, classified by the CYP2C19 phenotype. " 05/01/2015 - "There were no relationships between IL-1β and CYP2C19 in the treatment effect in mild reflux esophagitis." 02/01/2007 - "The purpose of the present study was to investigate whether CYP2C19 polymorphism had an influence on the remission of erosive reflux esophagitis (RE) during maintenance therapy with LPZ. " 09/01/2006 - "The present study was designed to investigate whether the CYP2C19 genotype is related to the healing of reflux esophagitis (RE) in treatment with RPZ 10 mg. One hundred and three Japanese patients with RE were treated with daily oral administration of 10 mg RPZ. " 10/01/2022 - "Vonoprazan and the CYP2C19 genotype-guided strategy were cost effective in the severe reflux esophagitis population, and in the reduction of the price of vonoprazan. "

Related Drugs and Biologics

1.	Clopidogrel (Plavix)
2.	Aspirin (Acetylsalicylic Acid)
3.	Cytochrome P-450 CYP3A
4.	Ticagrelor
5.	Rabeprazole (Aciphex)
6.	Cytochrome P-450 CYP2D6 (CYP2D6)
7.	Omeprazole (Prilosec)
8.	Cytochrome P-450 CYP2B6 (CYP2B6)
9.	Cytochrome P-450 CYP2C9
10.	Cytochrome P-450 Enzyme System (Cytochrome P450)

Related Therapies and Procedures

1.	Therapeutics
2.	Stents
3.	Secondary Prevention
4.	Percutaneous Coronary Intervention
5.	Glycemic Control